Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Cancer J. 2013 Jul-Aug;19(4):10.1097/PPO.0b013e31829d74b4. doi: 10.1097/PPO.0b013e31829d74b4

Table 1.

Summary of recently initiated trials of vaccine based therapies for mRCC. Note that several larger studies are detailed in the manuscript and in the figures enclosed below.

Study Number N Study Design/Agent Description
NCT0086230350 100 Randomized phase I/II
DC-CIK
IL-2/IFN-α

  • - Treat with DC loaded with DC vaccine in combo with CIK

  • - 1 ° EP: clinical RR, PFS, OS

  • - 2 ° EP: cellular immune RR and safety
NCT0152282051 20 Phase I
Sirolimus
DEC-205-NY-ESO-1 fusion
protein vaccine

  • - Solid tumors at high risks of recurrence or minimal residual disease

  • - 1 ° EP: safety of vaccine with and without sirolimus, toxicity

  • - 2 ° EP: assess specific cellular and humoral immunity

  • - 3 ° EP: time to disease progression
NCT0091391352 24 Phase 2
DC vaccine
Bevacizumab
IL-2
IFN-α

  • - Metastatic RCC

  • - 1 ° EP: clinical RR and PFS

  • - 2 ° EP: toxicity

  • - 3 ° EP: treatment related response